rs3734254 — PPARD T+294C

PPARD 3'UTR variant that reduces fatty acid oxidation capacity and blunts the metabolic response to lifestyle intervention

See your personal result for PPARD

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

PPARD T+294C — When Your Metabolic Furnace Burns Cooler

Peroxisome proliferator-activated receptor delta (PPARδ) is the master regulator of fatty acid beta-oxidation11 Fatty acid beta-oxidation is the process of breaking down fat molecules into acetyl-CoA for energy production, primarily in skeletal muscle and heart in skeletal muscle, heart, and liver. Think of it as the dial controlling how efficiently your body uses fat as fuel. PPARδ activation boosts fat burning, preserves insulin sensitivity, improves cholesterol profiles, and supports endurance capacity. The rs3734254 T+294C variant sits in the 3' untranslated region of PPARD and appears to reduce PPARD transcript stability or expression — subtly turning that dial down.

The Mechanism

The T+294C variant lies within the 3' UTR (untranslated region) of the PPARD gene on chromosome 6. The 3' UTR regulates mRNA stability, translational efficiency, and tissue-specific expression. Variants in this region can alter binding sites for microRNAs or RNA-binding proteins, changing how much functional PPARδ protein is ultimately produced. The C allele appears to reduce PPARD expression relative to the common T allele, particularly in metabolically active tissues. Because PPARδ directly drives the transcription of genes encoding enzymes involved in fatty acid oxidation (CPT1, HADHA), glucose uptake, and mitochondrial biogenesis, reduced expression impairs the full range of metabolic benefits downstream.

The Evidence

The clearest human evidence comes from the STOP-NIDDM trial22 STOP-NIDDM trial
Andrulionyte et al. SNPs of PPARD in combination with PGC-1A and PPARG2 predict conversion from IGT to T2D. Diabetes, 2006, which followed 769 individuals with impaired glucose tolerance. In the placebo group, carriers of the rare C allele at rs3734254 combined with the PGC-1A Gly482Ser allele (rs8192678) had up to 2.5-fold higher risk of progressing to type 2 diabetes compared to those carrying the common alleles.

The Tübingen Lifestyle Intervention Program Stefan et al.33 Stefan et al.
Stefan et al. Genetic variations in PPARD and PPARGC1A determine mitochondrial function and change in aerobic fitness and insulin sensitivity during lifestyle intervention. J Clin Endocrinol Metab, 2007 provided striking evidence of how much PPARD genotype constrains response to exercise and diet: after 9 months of supervised lifestyle intervention, participants carrying minor alleles in both PPARD and PPARGC1A gained only +4% insulin sensitivity, compared to +40% in major allele homozygotes — a tenfold difference in response.

Whole-body MRI data from Thamer et al.44 Thamer et al.
Thamer et al. Variations in PPARD determine the change in body composition during lifestyle intervention: a whole-body magnetic resonance study. J Clin Endocrinol Metab, 2008 showed that related PPARD SNPs independently predicted smaller reductions in visceral fat, hepatic fat, and less muscle gain during a lifestyle intervention program in 156 at-risk individuals — connecting this gene family to the distribution, not just amount, of fat.

Interestingly, the CC homozygous genotype was inversely associated with lung and upper aero-digestive tract cancer mortality in a large observational study Yang et al.55 Yang et al.
Yang et al. Polymorphisms of peroxisome proliferator-activated receptors and survival of lung cancer and upper aero-digestive tract cancers. Lung Cancer, 2014 (aHR=0.63 for lung cancer; 0.51 for UADT cancers), suggesting context-specific effects that differ between metabolic and oncological outcomes.

Practical Actions

For C allele carriers, the core challenge is that standard-intensity exercise and dietary changes produce a blunted metabolic return. The evidence from Stefan et al. and Thamer et al. points specifically toward the type and intensity of fat metabolism training: higher volumes of prolonged aerobic work at fat-burning intensities (Zone 2), together with a deliberate reduction in saturated fat and total long-chain fat load, may be needed to compensate for lower baseline PPARδ-driven fat oxidation.

Monitoring fasting glucose and insulin periodically gives early warning if metabolic progression is occurring — particularly important given the T2D conversion signal in the STOP-NIDDM trial.

Interactions

rs3734254 interacts most strongly with the PGC-1A Gly482Ser variant (rs8192678 in PPARGC1A) — the STOP-NIDDM data show that the two-gene combination produces risk far exceeding either alone. Within the PPARD gene itself, rs3734254 forms haplotypes with rs2267668, rs2016520, and rs6902123, the three fitness-category PPARD variants associated with aerobic fitness response and athlete performance.

Nutrient Interactions

dietary fat altered_metabolism
long-chain fatty acids impaired_conversion

Genotype Interpretations

What each possible genotype means for this variant.

TT Full Fat-Burning Capacity Normal

Common variant — optimal PPARD expression

You carry two copies of the common T allele, shared by approximately 58% of people globally (about 67% of Europeans). Your PPARD gene expression in skeletal muscle and liver is functioning at the population-typical level, supporting efficient fatty acid beta-oxidation and normal insulin sensitivity. Lifestyle interventions for metabolic health are expected to produce robust results in your case.

CT Reduced Fat-Burning Response Intermediate

One C allele — moderately reduced PPARδ expression

The PPARδ pathway is central to how skeletal muscle switches to fat as fuel during sustained exercise. Reduced PPARδ expression means less upregulation of fatty acid transport and oxidation enzymes (CPT1, HADHA) — your muscles preferentially rely more on glucose and produce less fat-derived ATP during aerobic work. Over time, this blunted fat oxidation contributes to greater ectopic fat accumulation (visceral and hepatic), which drives insulin resistance.

The Stefan et al. (2007) Tübingen data showed that PPARD minor-allele carriers achieved only a fraction of the insulin sensitivity gain that major-allele homozygotes reached after 9 months of supervised exercise and dietary intervention. This doesn't mean exercise is futile — it means the dose and type of exercise matter more for you than for TT carriers.

CC Significantly Reduced Fat-Burning Capacity Reduced

Two C alleles — substantially reduced PPARδ expression

At the population level, CC homozygotes are uncommon outside of African-ancestry populations where the C allele frequency reaches ~55%, making CC (~30%) a relatively common genotype in that context. For metabolic outcomes, the reduced PPARδ expression affects fat utilization across multiple tissues: skeletal muscle burns proportionally less fat and more glucose during aerobic work; the liver has reduced capacity to export hepatic fat; adipose tissue has lower lipolytic responsiveness. The cumulative effect is higher risk of ectopic fat deposition, visceral adiposity, and impaired insulin signaling.

The CC genotype was paradoxically associated with better cancer survival in the Yang et al. (2014) study (aHR=0.63 for lung cancer vs TT), possibly because PPARδ activity in some tumor contexts promotes proliferation — reduced PPARD expression may slow certain cancer-promoting pathways. This does not diminish the metabolic risk signal.

The Thamer et al. (2008) body-composition study showed that PPARD variants independently predicted smaller reductions in visceral and hepatic fat and less muscle gain even with full adherence to a supervised lifestyle program, suggesting CC carriers need higher exercise volumes or additional metabolic support to achieve results comparable to TT carriers.